Molecular epidemiology of drug resistance and population genetic structure of Pla

Pla耐药分子流行病学及群体遗传结构

基本信息

  • 批准号:
    7691785
  • 负责人:
  • 金额:
    $ 5.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Malaria remains a serious public health problem in China. In the subtropical Yunnan Province and the tropical Hainan Island of China, malaria has been the most endemic with high transmission of both Plasmodium falciparum and P. vivax. However, most of the attention in terms of research and interventions has been focused in Africa and Southeast Asia, very few studies of malaria in China have been conducted. Because of extensive use, chloroquine (CQ) has now lost its efficacy due to the emergence of resistant strains in most parts of the world. Meanwhile, suspension of the use of CQ has resulted in reappearance of CQ sensitivity. However, there were differences in the evolution of CQ resistance between parasites from Yunnan and Hainan, the exact mechanism needs to be investigated. Sulfadoxine-pyrimethamine (SP) targets the dhfr and dhps genes of P. falciparum, and point mutations that confer resistance have been widely reported worldwide. Documenting the identity and extent of SP resistance is also critical for policy decisions regarding antimalarial drugs. In addition, P. vivax causes a large burden of morbidity in the world including China but traditionally has been understudied. Based on these, our long-term goal of this proposal is 1) to identify single-nucleotide polymorphism (SNP) and characterize the geographic distribution of genetic diversity, population structure, and haplotype variability at drug resistant loci of P. falciparum from Yunnan and Hainan, China, 2) to examine the geographic population structure, levels of genetic diversity of P. vivax using microsatellite and SNP, and 3) to yield valuable information for making more effective malaria control policies in China. In the past several years we have developed the molecular methods to study the genetics, population diversity, and evolution of malaria parasites, and have done some preliminary studies on malaria field isolates from Yunnan and Hainan using genetic markers, thus enabling us to study the molecular epidemiology of these important malaria parasites in this proposal. The specific aims are to: 1. Determine genetic polymorphisms associated with CQ resistance (CQR) in P. falciparum field isolates from Yunnan and Hainan provinces, China. 2. Determine the point mutation prevalence in the dhfr (pyrimethamine drug resistance) and dhps (sulfadoxine drug resistance) genes associated with SP resistance in P. falciparum field isolates from Yunnan and Hainan provinces, China. 3. Assess the changes of P. vivax genotypes using pvcsp, pvmsp1, pvmsp3-1 genes, and microsatellite markers and determine the geographic structure and specific epidemiological characteristics of P. vivax transmission in Yunnan and Hainan, China. 1 PUBLIC HEALTH RELEVANCE: The project will be of significant benefit to public health programs aimed at identifying and combating drug-resistant malaria, and have the potential to benefit the health of a substantial proportion of the world's population. The data will provide valuable information for extending the life span of individual antimalarial drugs and developing more appropriate malaria control policies in China.
描述(申请人提供):疟疾在中国仍然是一个严重的公共卫生问题。在中国的亚热带云南省和热带海南岛,疟疾是最流行的地方病,恶性疟原虫和间日疟原虫的传播率都很高。然而,在研究和干预方面的大部分注意力都集中在非洲和东南亚,在中国进行的疟疾研究很少。由于广泛使用,氯喹(CQ)现在已经失去了它的效力,由于耐药菌株的出现,在世界大部分地区。与此同时,暂停使用CQ导致CQ敏感性重现。但云南和海南两地寄生虫对CQ的抗性进化存在差异,其确切机制有待进一步研究。磺胺嘧啶-乙胺嘧啶(SP)靶向恶性疟原虫的dhfr和dhps基因,并且赋予耐药性的点突变已在世界范围内被广泛报道。记录SP耐药性的特征和程度对于有关抗疟药物的政策决定也至关重要。此外,间日疟原虫在包括中国在内的世界范围内造成了巨大的发病负担,但传统上一直未得到充分研究。在此基础上,我们的长期目标是:1)鉴定云南和海南省恶性疟原虫耐药位点的单核苷酸多态性(SNP),并表征其遗传多样性、群体结构和单倍型变异的地理分布; 2)利用微卫星和SNP研究间日疟原虫的地理群体结构、遗传多样性水平,3)为制定更有效的疟疾防治政策提供有价值的信息。在过去的几年里,我们发展了研究疟原虫遗传学、种群多样性和进化的分子方法,并利用遗传标记对云南和海南的疟疾现场分离株进行了一些初步研究,从而使我们能够研究分子流行病学这些重要疟原虫在本提案中。具体目标是:1.确定中国云南和海南省恶性疟原虫田间分离株与CQ抗性(CQR)相关的遗传多态性。2.确定中国云南省和海南省恶性疟原虫现场分离株中与SP耐药相关的dhfr(乙胺嘧啶耐药)和dhps(磺胺嘧啶耐药)基因的点突变率。3.利用pvcsp、pvmsp 1、pvmsp 3 -1基因和微卫星标记评估云南和海南间日疟原虫基因型的变化,确定云南和海南间日疟原虫传播的地理结构和流行病学特征。1.公共卫生相关性:该项目将对旨在识别和防治抗药性疟疾的公共卫生计划产生重大效益,并有可能造福于世界上相当一部分人口的健康。这些数据将为延长单个抗疟药物的使用寿命和制定更合适的中国疟疾控制政策提供有价值的信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Fangli Lu其他文献

Fangli Lu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Fangli Lu', 18)}}的其他基金

Molecular epidemiology of drug resistance and population genetic structure of Pla
Pla耐药分子流行病学及群体遗传结构
  • 批准号:
    8497661
  • 财政年份:
    2009
  • 资助金额:
    $ 5.08万
  • 项目类别:
Molecular epidemiology of drug resistance and population genetic structure of Pla
Pla耐药分子流行病学及群体遗传结构
  • 批准号:
    8333855
  • 财政年份:
    2009
  • 资助金额:
    $ 5.08万
  • 项目类别:
Molecular epidemiology of drug resistance and population genetic structure of Pla
Pla耐药分子流行病学及群体遗传结构
  • 批准号:
    8103139
  • 财政年份:
    2009
  • 资助金额:
    $ 5.08万
  • 项目类别:

相似海外基金

Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
  • 批准号:
    MR/X030202/1
  • 财政年份:
    2023
  • 资助金额:
    $ 5.08万
  • 项目类别:
    Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
  • 批准号:
    10742205
  • 财政年份:
    2023
  • 资助金额:
    $ 5.08万
  • 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
  • 批准号:
    10635649
  • 财政年份:
    2023
  • 资助金额:
    $ 5.08万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10534667
  • 财政年份:
    2022
  • 资助金额:
    $ 5.08万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10533634
  • 财政年份:
    2022
  • 资助金额:
    $ 5.08万
  • 项目类别:
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
  • 批准号:
    2749037
  • 财政年份:
    2022
  • 资助金额:
    $ 5.08万
  • 项目类别:
    Studentship
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
  • 批准号:
    468862
  • 财政年份:
    2022
  • 资助金额:
    $ 5.08万
  • 项目类别:
    Operating Grants
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
  • 批准号:
    10646331
  • 财政年份:
    2022
  • 资助金额:
    $ 5.08万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10368441
  • 财政年份:
    2022
  • 资助金额:
    $ 5.08万
  • 项目类别:
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
  • 批准号:
    10494711
  • 财政年份:
    2022
  • 资助金额:
    $ 5.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了